Business, energy, technology, markets and global industry news from Business News Today

Genentech

PharmaDeviceNews Genentech
Pharma & Biotech

Genentech advances Gazyva toward first approval in primary membranous nephropathy after Phase III win

Discover how Genentech’s Gazyva Phase III data could reshape treatment goals in membranous nephropathy and what regulators and clinicians will watch next.

Read More
Pharma & Biotech

Can Genentech’s CT-388 challenge obesity drug giants with 22.5% weight loss and β-arrestin bias?

Genentech’s CT-388 hit 22.5% weight loss in Phase II. Find out what this means for obesity drugs, clinical durability, and market strategy in 2026.

Read More
Pharma & Biotech

What Genentech’s Lunsumio VELO approval means for relapsed follicular lymphoma treatment

FDA approves subcutaneous Lunsumio VELO for relapsed follicular lymphoma. Explore what this changes for bispecific antibodies and outpatient cancer care.

Read More